AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32074275 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NPM1 mutations.
Number of subjects: 46
Study 32074275 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IDH2 mutations.
Number of subjects: 46
Study 32074275 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TP53 mutations.
Number of subjects: 46
Study 32074275 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day induction death rate.
Number of subjects: 46
Study 32074277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion
Number of subjects: 115
Study 32074665 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) foam applied once daily for ≤4 weeks
Number of subjects: 106
Study 32074665 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) foam
Number of subjects: 106
Study 32075470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling, specific dosage and duration not mentioned.
Number of subjects: 0
Study 32075593 — intervention group
Group type: EXPERIMENTAL
Intervention: MAMAACT intervention (training course for midwives, leaflet, mobile application, additional visit time)
Number of subjects: 18
Study 32075601 — intervention group
Group type: EXPERIMENTAL
Intervention: NASCITA cohort study
Number of subjects: 5000
Study 32075647 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese version of the Resilience Scale-14
Number of subjects: 1816
Study 32075790 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics during pregnancy (first trimester)
Number of subjects: 104605
Study 32075790 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics during pregnancy (any trimester)
Number of subjects: 104605
Study 32075790 — intervention group
Group type: COMPARATOR
Intervention: Penicillin antibiotics during pregnancy
Number of subjects: 104605
Study 32075821 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering model with three clusters: 'Early Onset and Short Course' (47.5%), 'Early Onset and Long Course' (35%), 'Late Onset and Short Course' (17.5%).
Number of subjects: 628
Study 32075821 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling characteristics analysis.
Number of subjects: 628
Study 32075821 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple screening based on gambling characteristics.
Number of subjects: 628
Study 32075821 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy measures targeting gambling characteristics.
Number of subjects: 628
Study 32075827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians
Number of subjects: 5155
Study 32075827 — intervention group
Group type: COMPARATOR
Intervention: Revised Trauma Score (RTS)
Number of subjects: 5155
Study 32075827 — intervention group
Group type: COMPARATOR
Intervention: Glasgow Coma Scale, Age and Systolic Blood Pressure (GAP) score
Number of subjects: 5155
Study 32075827 — intervention group
Group type: COMPARATOR
Intervention: Kampala Trauma Score (KTS)
Number of subjects: 5155
Study 32075827 — intervention group
Group type: COMPARATOR
Intervention: Gerdin
Number of subjects: 5155
Study 32075841 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs' sense of alarm (measured using the Gut Feelings Questionnaire)
Number of subjects: 235
Study 32075847 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of urban trails (5-8 km long, paved, multiuse) built between 2008 and 2010.
Number of subjects: 0
Study 32076124 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3965 (mono-carboxylase transporter 1 inhibitor)
Number of subjects: 1
Study 32076124 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment
Number of subjects: 1
Study 32076124 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET scan
Number of subjects: 1
Study 32076124 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature review
Number of subjects: 1
Study 32076473 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dilatation (non-compliant balloon inflated to >16 atm pressure)
Number of subjects: 41
Study 32076473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no post-dilatation)
Number of subjects: 41
Study 32076473 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dilatation
Number of subjects: 41
Study 32076473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 32076567 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliant balloons (NCBs)
Number of subjects: 104
Study 32076567 — intervention group
Group type: COMPARATOR
Intervention: Semi-compliant balloons (SCBs)
Number of subjects: 104
Study 32076579 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 91
Study 32076889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad (4 mg) with oxaprozin
Number of subjects: 12
Study 32076889 — intervention group
Group type: COMPARATOR
Intervention: Dotinurad (4 mg) alone
Number of subjects: 12
Study 32077361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ('primed') decitabine in combination with CLAG-M
Number of subjects: 0
Study 32077361 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent decitabine in combination with CLAG-M
Number of subjects: 0
Study 32077442 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher social anxiety in adolescents less than 13 years of age
Number of subjects: 0
Study 32077442 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents aged 13 and older
Number of subjects: 0
Study 32077603 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated-interferon (PEG-IFN) for 48 weeks
Number of subjects: 15000000
Study 32077603 — intervention group
Group type: EXPERIMENTAL
Intervention: bulevirtide (entry inhibitor)
Number of subjects: 15000000
Study 32077603 — intervention group
Group type: EXPERIMENTAL
Intervention: lonafarnib (prenylation inhibitor)
Number of subjects: 15000000
Study 32077603 — intervention group
Group type: EXPERIMENTAL
Intervention: REP 2139 (HBsAg release inhibitor)
Number of subjects: 15000000
Study 32077779 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic transplantation of limbal stem cells expanded on amniotic membrane
Number of subjects: 0
Study 32077895 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin (1.3 mg/m2 starting dose, 1.5 mg/m2 dose level +1, 1.1 mg/m2 dose level -1) plus radiotherapy (30 Gy, 3 Gy/d for 10 days)
Number of subjects: 45
Study 32077895 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin (1.3 mg/m2 starting dose, 1.5 mg/m2 dose level +1, 1.1 mg/m2 dose level -1)
Number of subjects: 45
Study 32077948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for women
Number of subjects: 251
Study 32077948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for men
Number of subjects: 251
Study 32078016 — intervention group
Group type: EXPERIMENTAL
Intervention: DC vaccines transfected with personalized TAA panels
Number of subjects: 10
Study 32078016 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide, poly I:C, imiquimod and anti-PD-1 antibody (in combination with DC vaccines)
Number of subjects: 10
Study 32078124 — intervention group
Group type: EXPERIMENTAL
Intervention: Split first dose of intravenous daratumumab (16 mg/kg split into two 8 mg/kg doses on Days 1 and 2)
Number of subjects: 0
Study 32078124 — intervention group
Group type: COMPARATOR
Intervention: Single first dose of intravenous daratumumab (16 mg/kg)
Number of subjects: 0
Study 32078124 — intervention group
Group type: EXPERIMENTAL
Intervention: Split first dose of intravenous daratumumab
Number of subjects: 0
Study 32078124 — intervention group
Group type: COMPARATOR
Intervention: Single first dose of intravenous daratumumab
Number of subjects: 0
Study 32078362 — intervention group
Group type: EXPERIMENTAL
Intervention: LICU system
Number of subjects: 52
Study 32078362 — intervention group
Group type: EXPERIMENTAL
Intervention: LICU system with enhanced software
Number of subjects: 52
Study 32078381 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased maternal systolic blood pressure
Number of subjects: 301
Study 32078381 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased maternal diastolic blood pressure
Number of subjects: 301
Study 32078381 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased maternal systolic and diastolic blood pressure
Number of subjects: 301
Study 32078781 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk feeding
Number of subjects: 24113
Study 32078781 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive human milk feeding
Number of subjects: 24113
Study 32078781 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk feeding rates
Number of subjects: 24113
Study 32078781 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk feeding practices
Number of subjects: 24113
Study 32078781 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk feeding rates over time
Number of subjects: 24113
Study 32078808 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32078813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (adults 60 mg, children <16 years 40 mg)
Number of subjects: 90
Study 32079476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6784
Study 32079476 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifiable bleeding risk factors (heavy alcohol use, uncontrolled hypertension, concomitant treatment with antiplatelets, NSAIDs, or paracetamol)
Number of subjects: 6784
Study 32079476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmodifiable bleeding risk factors (increasing age, heart failure, vascular disease)
Number of subjects: 6784
Study 32079557 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 287079
Study 32079557 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy
Number of subjects: 287079
Study 32079624 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of adjuvant trastuzumab
Number of subjects: 11250
Study 32079624 — intervention group
Group type: COMPARATOR
Intervention: Shorter trastuzumab regimens
Number of subjects: 11250
Study 32079690 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with focus on T-cell immune checkpoint molecules
Number of subjects: 188
Study 32079690 — intervention group
Group type: EXPERIMENTAL
Intervention: TME immune cell signature
Number of subjects: 188
Study 32079702 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA analysis after 2 cycles of chemotherapy (C2)
Number of subjects: 60
Study 32079702 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA analysis at diagnosis
Number of subjects: 60
Study 32079709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 32079709 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors (olaparib, niraparib, rucaparib)
Number of subjects: 0
Study 32079709 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous recombination repair deficiency
Number of subjects: 0
Study 32080086 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus eluting stents (PF-SES)
Number of subjects: 7243
Study 32080135 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute with 18% sodium chloride for 8 weeks
Number of subjects: 43
Study 32080210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat combined with ixazomib
Number of subjects: 70
Study 32080210 — intervention group
Group type: COMPARATOR
Intervention: Vorinostat combined with pazopanib
Number of subjects: 70
Study 32080720 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Training
Number of subjects: 0
Study 32080720 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 32080809 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized web-based recurrence risk assessment tool
Number of subjects: 8249
Study 32081289 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 32081289 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe/Simvastatin
Number of subjects: 0
Study 32082310 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement activation assessment
Number of subjects: 0
Study 32082606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotics
Number of subjects: 60
Study 32082606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 60
Study 32082606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study 32083013 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Immunotherapy
Number of subjects: 0
Study 32083013 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32083104 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine-Assisted Activities and Brain-Building Activities (GaitWay block)
Number of subjects: 25
Study 32083104 — intervention group
Group type: COMPARATOR
Intervention: Equine-Assisted Activities only
Number of subjects: 25
Study 32083104 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 32083104 — intervention group
Group type: COMPARATOR
Intervention: Washout
Number of subjects: 25
Study 32083219 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation sessions implemented before informed consent and randomization
Number of subjects: 467
Study 32083219 — intervention group
Group type: COMPARATOR
Intervention: Before orientation sessions
Number of subjects: 467
Study 32083583 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid β stiffness index
Number of subjects: 32
Study 32083583 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid distensibility
Number of subjects: 32
Study 32083583 — intervention group
Group type: EXPERIMENTAL
Intervention: cfPWV
Number of subjects: 32
Study 32083996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine with dexamethasone (ben-dex)
Number of subjects: 31
Study 32084260 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTCT grading system for CRS
Number of subjects: 102
Study 32084260 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTCT grading system for ICANS
Number of subjects: 102
Study 32084260 — intervention group
Group type: COMPARATOR
Intervention: Comparison of grading systems for CRS
Number of subjects: 102
Study 32084260 — intervention group
Group type: COMPARATOR
Intervention: Comparison of grading systems for ICANS
Number of subjects: 102
Study 32084260 — intervention group
Group type: COMPARATOR
Intervention: Grade comparison for CRS
Number of subjects: 102
Study 32084260 — intervention group
Group type: COMPARATOR
Intervention: Grade comparison for ICANS
Number of subjects: 102
Study 32084274 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction cup method to increase IOP
Number of subjects: 15
Study 32084409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-DS (adenovirus-mediated double-suicide gene therapy) injected into pancreatic mass with EUS-guided fine needles, combined with oral 5-fluorocytosine and valganciclovir, and standard dose of intravenous gemcitabine.
Number of subjects: 11
Study 32085707 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-delivered intervention
Number of subjects: 105
Study 32085865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2240
Study 32085865 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 2240
Study 32085891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin monotherapy, administered intravenously at 3.2 mg/m²
Number of subjects: 42
Study 32085892 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant FOLFOX or FLOX (2004-2009)
Number of subjects: 6501
Study 32085892 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant FOLFOX or FLOX (1998-2003)
Number of subjects: 6501
Study 32086343 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (3 mg/kg once every two weeks)
Number of subjects: 40
Study 32086361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention using the Drug Burden Index (DBI) Calculator
Number of subjects: 160
Study 32086361 — intervention group
Group type: COMPARATOR
Intervention: Preintervention retrospective control cohort
Number of subjects: 160
Study 32086522 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 30
Study 32086522 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 30
Study 32086697 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (double-scattered conformal proton therapy) to a mean dose of 54 GyRBE in 1.8 GyRBE/fraction (range 52.2-54 GyRBE)
Number of subjects: 14
Study 32086697 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (double-scattered conformal proton therapy)
Number of subjects: 14
Study 32087152 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation
Number of subjects: 70379
Study 32087152 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP engagement at week 4
Number of subjects: 70379
Study 32087152 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication refills at week 4
Number of subjects: 70379
Study 32087152 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence at week 4
Number of subjects: 70379
Study 32087152 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP engagement at week 72
Number of subjects: 70379
Study 32087152 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication refills at week 72
Number of subjects: 70379
Study 32087152 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence at week 72
Number of subjects: 70379
Study 32087152 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence with tenofovir concentrations
Number of subjects: 70379
Study 32087152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to PrEP
Number of subjects: 70379
Study 32087304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib and entinostat combination
Number of subjects: 0
Study 32087715 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (50 mg for 10-<25 kg, 87.5 mg for 25-<50 kg)
Number of subjects: 219
Study 32087715 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (with/without methotrexate and/or low-dose corticosteroids)
Number of subjects: 219
Study 32087733 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV + PPV23 in abatacept
Number of subjects: 108
Study 32087733 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV + PPV23 in cDMARDs
Number of subjects: 108
Study 32087733 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV + PPV23 in controls
Number of subjects: 108
Study 32087733 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV + PPV23 in rituximab
Number of subjects: 108
Study 32087733 — intervention group
Group type: COMPARATOR
Intervention: PCV + PPV23 in all treatment groups
Number of subjects: 108
Study 32087733 — intervention group
Group type: COMPARATOR
Intervention: OPA assay in rituximab
Number of subjects: 108
Study 32087733 — intervention group
Group type: COMPARATOR
Intervention: OPA assay in abatacept
Number of subjects: 108
Study 32087733 — intervention group
Group type: COMPARATOR
Intervention: OPA assay in cDMARDs
Number of subjects: 108
Study 32087839 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalist model (BI delivered by primary care provider)
Number of subjects: 9639
Study 32087839 — intervention group
Group type: COMPARATOR
Intervention: Specialist model (BI delivered by behavioral health counselor)
Number of subjects: 9639
Study 32087995 — intervention group
Group type: EXPERIMENTAL
Intervention: CT Leaman score
Number of subjects: 169
Study 32088180 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive strategies (neuromuscular blockade, prone position, extracorporeal membrane oxygenation, inhaled vasodilators, high-frequency ventilation)
Number of subjects: 1146
Study 32088180 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive strategies
Number of subjects: 1146
Study 32088180 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized adjuncts
Number of subjects: 1146
Study 32088255 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct Medical Condition (CMC)
Number of subjects: 433
Study 32088255 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs/Symptoms (SS)
Number of subjects: 433
Study 32088255 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect Medical Condition (IMC)
Number of subjects: 433
Study 32088255 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls with chief complaint description pursued
Number of subjects: 433
Study 32088255 — intervention group
Group type: COMPARATOR
Intervention: Calls without chief complaint description pursued
Number of subjects: 433
Study 32088255 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls with SS chief complaints
Number of subjects: 433
Study 32088255 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls with IMC chief complaints
Number of subjects: 433
Study 32088255 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls with CMC chief complaints
Number of subjects: 433
Study 32088322 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS-6150 (4 mg, 3 mg, or 6 mg/vaccination, administered 4 times at 4-week intervals, followed by a 6 mg boost at 24 weeks)
Number of subjects: 20
Study 32088322 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS-6150
Number of subjects: 20
Study 32088663 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan
Number of subjects: 300
Study 32088663 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (active control)
Number of subjects: 300
Study 32088879 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemia overtreatment (HbA1c < 6.5% with ≥ 2 oral antihyperglycemics or insulin)
Number of subjects: 1264
Study 32088879 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure overtreatment (SBP < 120 mmHg or DBP < 65 mmHg with ≥ 2 drugs)
Number of subjects: 1264
Study 32088879 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemia undertreatment (HbA1c > 9%)
Number of subjects: 1264
Study 32088879 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure undertreatment (SBP > 150 mmHg or DBP > 90 mmHg)
Number of subjects: 1264
Study 32088879 — intervention group
Group type: EXPERIMENTAL
Intervention: Deintensification of glycemia treatment
Number of subjects: 1264